Wells Fargo analyst Derek Archila lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $24 from $44 and keeps an Overweight rating on the shares. The updated KYV-101 data at ACR should be incremental and additional durability data for the target dose should offer insight into the durability and quality of remission, the analyst tells investors in a research note. This could offer modest upside for shares, the firm adds.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX: